CSF2 and congenital rubella syndrome: Other mAbs targeting GM-CSF (lenzilumab), IL-1 receptor (anakinra) and catecholamines (atrial natriuretic peptide), which induce CRS through a self-augmenting loop, are also employed to break the feedback loop in clinical settings (66, 67).